Sequana Medical’s strategic review could attract interest from potential acquirers or investors, particularly those focused on innovative medical technologies.
Ghent-based Sequana Medical NV (Euronext Brussels: SEQUA), a leader in treating drug-resistant fluid overload in liver disease, heart failure, and cancer, announced on April 28, 2026, that it is evaluating a range of financial and strategic alternatives to secure its future.
The company, advised by external consultants, is considering options such as financing transactions, corporate restructuring, or asset sales. While no final decisions have been made, the review underscores Sequana Medical’s proactive approach to addressing its current financial challenges and positioning itself for long-term sustainability.
The company’s upcoming annual general shareholders’ meeting, scheduled for May 28, 2026, will proceed without the usual review of its 2025 financial statements, which remain pending due to the ongoing strategic assessment. The board of directors plans to adjourn related agenda items until the financial reports are finalized. Preliminary data indicates that Sequana Medical’s statutory net equity has turned negative, prompting the board to propose continuing the company’s operations under Article 7:228 of the Belgian Companies and Associations Code—a move that will require shareholder approval.
Industry observers note that Sequana Medical’s strategic review could attract interest from potential acquirers or investors, particularly those focused on innovative medical technologies. As the company navigates this critical phase, stakeholders will closely monitor developments, especially given its pioneering role in addressing unmet medical needs. The outcome of this process may significantly impact the Belgian M&A landscape, offering opportunities for consolidation or partnership in the biotech sector.
READ ALSO: Coultreon Biopharma raises 125 million dollars in Series A Financing to advance immunology pipeline
